On September 25, 2026, the European Commission formally revoked the marketing authorization for Hansoh Pharma's almonertinib mesylate tablets, sold overseas under the brand name Aumseqa®, merely seven months after the product won approval in February. According to a company announcement, the revocation was triggered by a lawsuit filed by AstraZeneca with the EU General Court, with the core dispute centering on osimertinib clinical data cited as background reference in the 2022 filing, which at the time of submission was still within the EU's eight-year data exclusivity period—although that period expired in 2024, the EU nevertheless determined the marketing approval contained procedural flaws. The incident itself has nothing to do with drug quality, safety, or efficacy, yet it lays bare deeper problems in Hansoh Pharma's overseas regulatory compliance, risk foresight, and execution of its internationalization strategy.
Regulatory Oversight Gaps Expose Weaknesses in Overseas Risk Control
The most immediate issue in this incident is that Hansoh Pharma did not adequately understand the boundaries of EU pharmaceutical regulatory rules, and its compliance risk controls for overseas filings showed a clear lack of upfront safeguards. As an original innovative drug with a complete set of proprietary Phase III clinical data, almonertinib could have relied entirely on its own trial data to support its marketing application, yet it cited competitor data that was still under exclusivity in the background discussion section. This minor flaw did not affect the drug's clinical value, but it happened to cross the red line of EU data protection rules, giving competitors a lever to influence the regulatory decision. In essence, this reflects the company's insufficient understanding of the complexity of the EU regulatory system—data exclusivity rules do not only bind generics; any citation in an originator drug filing must be strictly checked against protection periods, yet domestic pharmaceutical companies generally focus more on the quality of clinical data itself and easily overlook such procedural compliance risks.
More fundamentally, the company's emergency response mechanism for overseas regulatory conflicts is clearly lacking. AstraZeneca filed its lawsuit as early as May 2026, and the European Commission initiated the revocation procedure without waiting for the court's ruling. During this period, Hansoh Pharma failed to delay or block the revocation through effective legal intervention, supplementary materials, or communicative defense, and ultimately had to passively accept the outcome and announce a refiling. This means the company has shortcomings in its European market regulatory affairs team, legal resource reserves, and crisis response plans, and cannot react quickly when facing legal challenges from a giant. For domestic pharmaceutical companies accelerating their internationalization, such non-technical barriers are often no less damaging than clinical failures, and a lagging risk control system will directly amplify the scope of impact of compliance risks.
Pressure on Internationalization Strategy and Long-Term Competitive Landscape Risks
The impact of the EU withdrawal of almonertinib goes far beyond the delay of a single product's launch; it directly strikes at the pace of Hansoh Pharma's internationalization strategy and signals that domestic innovative drugs going global will face even fiercer multi-dimensional resistance from giants. As China's first homegrown third-generation EGFR-TKI, almonertinib is the vanguard product of Hansoh Pharma's internationalization, carrying the strategic significance of breaking the stereotype that domestic innovative drugs can only go to emerging markets. This revocation delays its European commercialization process by at least one to two years, not only missing the best window for market introduction but also disrupting the company's layout rhythm of using the European market as a hub to reach globally. Although the UK approval remains valid, a single market of limited size cannot support the strategic weight of internationalization.
More alarmingly, this incident marks that domestic innovative drugs going global have entered the zone of direct confrontation with international giants. AstraZeneca's osimertinib is the global benchmark for third-generation EGFR-TKIs, with global sales of $3.775 billion in the first half of 2026, and Europe is one of its core markets. Almonertinib entered Europe with advantages in efficacy and safety, directly threatening osimertinib's market position, so the giant's use of legal means to delay competitor access is essentially an extension of market competition. This means that Hansoh Pharma's subsequent pipeline expansion overseas, as well as other domestic innovative drugs of the same class going global, may encounter multi-dimensional resistance including patent litigation, data protection challenges, and regulatory lobbying. Competition has extended from clinical efficacy to a comprehensive contest of compliance, legal, and public affairs capabilities.
In addition, the incident has exacerbated uncertainty over the company's internationalization input-output ratio. Resubmitting a marketing application requires additional compliance and time costs, and even if approved again, the pace of market education and channel building has already been disrupted. Coupled with tightening payment conditions in the European pharmaceutical market and expectations of centralized procurement price cuts, almonertinib's overseas profitability cycle will be further prolonged. In the short term, the product has not yet generated overseas sales, so it does not constitute a direct blow to the company's performance, but internationalization progress falling short of expectations will affect the market's valuation judgment of the company's innovation value and also weaken the confidence premium for subsequent pipeline globalization.
Overall, the EU withdrawal of almonertinib is a typical growing pain in the process of domestic innovative drugs going global. It is not a product failure but a warning about compliance and risk control capabilities. For Hansoh Pharma, the urgent task is not only to complete the refiling as soon as possible but also to use this opportunity to shore up its overseas regulatory compliance system and establish risk foresight and response mechanisms for competition with international giants.